ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,307.69
      1.16%
      US Tech 100
      18,112.80
      1.55%
      Dow Jones
      39,904.86
      0.88%
      Brent Oil
      82.695
      0.18%
      Bitcoin
      66,026.72
      7.30%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      2:30PMiHub NewswireFeaturedIntegrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share
      05/15/202411:44AMBusiness WireIncyte présentera les données de son portefeuille d'oncologie lors de la réunion annuelle 2024 de l'ASCO et du congrès EHA2024NASDAQ:INCYIncyte Corporation
      05/15/202411:10AMEdgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:INCYIncyte Corporation
      05/14/20245:00PMBusiness WireIncyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 CongressNASDAQ:INCYIncyte Corporation
      05/14/20249:05AMIH Market NewsProducer Price Inflation Data May Weigh On Wall StreetNASDAQ:INCYIncyte Corporation
      05/13/20246:06PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:INCYIncyte Corporation
      05/13/20244:34PMIH Market NewsDow Snaps Eight-Day Winning Streak After Lackluster SessionNASDAQ:INCYIncyte Corporation
      05/13/202411:19AMEdgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:INCYIncyte Corporation
      05/13/20247:19AMEdgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:INCYIncyte Corporation
      05/13/20247:18AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
      05/13/20247:00AMBusiness WireIncyte Announces Intention to Buy Back up to $2.0 Billion of its Common StockNASDAQ:INCYIncyte Corporation
      05/09/20246:40PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:INCYIncyte Corporation
      05/09/20246:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      05/02/20248:00AMBusiness WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
      04/30/20247:00AMBusiness WireIncyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      04/23/20246:11PMBusiness WireIncyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorieNASDAQ:INCYIncyte Corporation
      04/23/20246:01PMBusiness WireIncyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekanntNASDAQ:INCYIncyte Corporation
      04/23/20247:00AMBusiness WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsNASDAQ:INCYIncyte Corporation
      04/11/20248:00AMBusiness WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
      04/01/20248:30AMBusiness WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaNASDAQ:INCYIncyte Corporation
      03/29/20244:30PMBusiness WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
      03/11/20248:57AMBusiness WireIncyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekanntNASDAQ:INCYIncyte Corporation
      03/11/20248:57AMBusiness WireIncyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modéréeNASDAQ:INCYIncyte Corporation
      03/11/20246:06AMBusiness WireIncyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaireNASDAQ:INCYIncyte Corporation
      03/11/20245:53AMBusiness WireIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vorNASDAQ:INCYIncyte Corporation
      03/10/20244:05PMBusiness WireIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
      03/10/20244:05PMBusiness WireIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisNASDAQ:INCYIncyte Corporation
      03/04/20242:38PMBusiness WireDe nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
      03/04/20242:02PMBusiness WireNeue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
      03/04/20248:00AMBusiness WireNew Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY